Search results

Publications highlights three young researchers

ANSTO's Mo-99 manufacturing facility secures Australia’s ability to produce Mo-99 to meet current and future domestic demand and provide a significant proportion to support global demand.

ANSTO has responsibilities mandated by the Australian Government for the maintenance of the national measurement standard for radioactivity.

Commitment to undertake health research.

ANSTO has safely managed its radioactive waste for over 60 years. Waste is managed in accordance with national and international standards.

Michael Druce has been awarded a Public Service Medal in the Australia Day honours for his contribution to nuclear medicine production.

ANSTO’s OPAL multi-purpose research reactor at Lucas Heights has officially returned to power and recommenced operations, following a months-long planned shutdown to carry out essential maintenance and upgrades.

Award recipients Dr Richard Garrett and Dr Nigel Lengkeek with Dr Tien Pham will deliver a Distinguished Lecture on 15 November at ANSTO.

In January 2026, Mr Michael Quigley AM, ANSTO Board Chair, shared ANSTO's Statement of Intent with the Minister for Industry and Innovation, and Minister for Science.

ANSTO has been licensed as the Australian manufacturing partner of an innovative, non-invasive treatment for non-melanoma skin cancer (NMSC).

ANSTO is a highly regulated organisation. Our governance system and processes provide critical guidance to effectively manage ANSTO’s activities. This section outlines the processes and systems that are in place to provide assurance to Government, our stakeholders and the community that we are working within our regulated and mandated requirements.

ANSTO has almost seventy years of experience in advancing an understanding of the management of spent nuclear fuel and delivering safe and reliable forms for radioactive waste. 

Potential new treatments and tools for depression under development.